BioNTech SE
NASDAQ:BNTX
BioNTech SE
NASDAQ:BNTX
Price:
92.13 USD
-0.16%
Market Closed
Updated:
May 15, 2024
BioNTech SE
Cash from Financing Activities
|
BioNTech SE
Cash from Financing Activities Peer Comparison
Comparables:
MOR
CVAC
IMTX
BIO
FYB
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
BioNTech SE
NASDAQ:BNTX
|
Cash from Financing Activities
-€778.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
MorphoSys AG
XETRA:MOR
|
Cash from Financing Activities
€91.8m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-3%
|
|
|
CureVac NV
NASDAQ:CVAC
|
Cash from Financing Activities
€230.9m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Cash from Financing Activities
€84.5m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Cash from Financing Activities
-€6.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Formycon AG
XETRA:FYB
|
Cash from Financing Activities
€44.4m
|
CAGR 3-Years
22%
|
CAGR 5-Years
139%
|
CAGR 10-Years
N/A
|
See Also
What is BioNTech SE's Cash from Financing Activities?
Cash from Financing Activities
-778.6m
EUR
-778.6m
EUR
Based on the financial report for Dec 31, 2023, BioNTech SE's Cash from Financing Activities amounts to -778.6m EUR.
What is BioNTech SE's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 1Y
45%
45%
Over the last year, the Cash from Financing Activities growth was 45%.
You don't have any saved screeners yet
